Roivant discontinues blood cancer program as it fails to revive old Eisai drug, to dissolve Hemavant
Roivant disclosed Tuesday morning that it has stopped work on a treatment for myelodysplastic syndromes, a precursor disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
